poisar

Stocks · News reference

HSBC Maintains Hold on Pfizer, Raises Price Target to $30

Benzinga Newsdesk

HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PFE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY
  2. Bcc Research

    AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors

    Artificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.

    PFENVDADNAIMDCY
  3. National Association Of Specialty Pharmacy (Nasp)

    NASP Announces 2026 Industry Award Winners at Record-Breaking inSPire2026 Conference

    The National Association of Specialty Pharmacy (NASP) recognized industry leaders and organizations at its annual conference in National Harbor, Maryland. Award recipients included Optum Specialty Pharmacy (Specialty Pharmacy of the Year), Van Chau from UC Davis Health (Pharmacist of the Year), and Pfizer (Manufacturer of the Year), among others. The record-breaking conference attracted over 2,400 specialty pharmacy professionals.

    UNHPFE
  4. David Jagielski, Cpa

    Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

    The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.

    LLYPFE